ITGR
Integer Holdings Corporation
NYSE · Healthcare · Medical - Devices · US
$126.50
+0.80%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.8B | 1.8B | 1.7B | 1.6B | 1.3B |
| Cost of Revenue | 1.4B | 1.4B | 1.3B | 1.1B | 984.6M |
| Gross Profit | 436.9M | 425.8M | 461.2M | 411.5M | 346.7M |
| Operating Expenses | |||||
| R&D Expense | 48.6M | 46.3M | 53.4M | 62.0M | 59.8M |
| SG&A Expense | 194.4M | 162.6M | 184.3M | 171.5M | 157.4M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 19.5M | 7.6M | 15.2M | 14.8M | 16.9M |
| Total Operating Expenses | 262.5M | 216.5M | 252.9M | 248.2M | 234.0M |
| Cost and Expenses | 1.7B | 1.6B | 1.5B | 1.4B | 1.2B |
| Operating Income (EBIT) | 174.4M | 209.3M | 208.2M | 163.3M | 112.7M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 38.5M | 42.3M | 56.4M | 53.4M | 37.3M |
| Net Interest Income | (38.5M) | (42.3M) | (56.4M) | (53.4M) | (37.3M) |
| Other Non-Op Income/Expense | (38.0M) | (83.9M) | (60.7M) | (57.9M) | (44.0M) |
| Non-Operating Income (excl Interest) | (532.0K) | 41.6M | (15.0M) | (15.4M) | (18.2M) |
| EBT (Pre-Tax Income) | 136.4M | 125.4M | 147.6M | 105.4M | 68.7M |
| Income Tax Expense | 8.0M | 22.6M | 26.5M | 16.2M | 8.9M |
| Bottom Line | |||||
| Net Income | 128.4M | 102.8M | 119.9M | 90.7M | 66.4M |
| Earnings from Cont. Ops | 128.4M | 102.8M | 121.1M | 89.1M | 59.7M |
| Earnings from Discont. Ops | — | (68.0K) | (1.2M) | 1.5M | 6.6M |
| Bottom Line Net Income | 128.4M | 102.9M | 119.9M | 90.7M | 66.4M |
| Per Share | |||||
| Basic EPS | $3.69 | $2.96 | $3.60 | $2.72 | $1.97 |
| Diluted EPS | $3.66 | $2.89 | $3.40 | $2.69 | $1.96 |
| Revenue Per Share | $54.14 | $53.16 | $51.09 | $46.69 | $40.19 |
| Shares | |||||
| Basic Shares Outstanding | 34.0M | 34.7M | 33.6M | 33.3M | 33.1M |
| Diluted Shares Outstanding | 34.1M | 35.6M | 35.6M | 33.8M | 33.4M |
| Profitability Metrics | |||||
| EBITDA | 313.0M | 293.7M | 332.9M | 275.7M | 221.7M |
| D&A | 138.1M | 126.0M | 109.7M | 97.0M | 90.9M |
| EBIT | 174.9M | 167.7M | 223.2M | 178.7M | 130.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jul 1, 2026